26 Nov

Change of Directors Interest Notice

Appendix 3Y Change of Directo r’s Interest Notice + See chapter 19 f o r d efined terms. 01/01/20 11 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/ 0 9/01 Amended 01/01/11 Name of entity Medical Developments International Limited ABN 14 106 340 667 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the direc tor for the purposes of section 205G of the Corporations Act. Name of Director Gordon Naylor Date of last notice 7 September 2021 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in th e t r u st made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest 1. Ind i rec t 2. Ind irect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the re l evant interest. 1. N aylor - S tewart I nvestments P t y L td a s T rustee for N aylor - S tewart F amily T rust 2. A ustr alia n Executor T rus tees L imited Naylor - Stewart Family Supe r Fund Date of change 2 2 - 2 5 November 202 1 No. of securities held prior to change 1. 2 6 6,615 2. 263,695 Class Fully P a i d Or dinary Shares Number acquired 38,505 Number disposed Nil Value/Consideration Note: If c o nsi dera tion is non - cash, provide details and estimated valuation 2 2 /11/21 – 6 shares @ $ 4 . 880 per share 2 3 / 11 /21 – 5 , 458 shares @ $ 4.900 per share 2 4 / 11 /2 1 – 23, 825 shares @ $ 4 . 900 per share 2 5 / 11 /21 – 9 , 216 shares @ $ 4.9 26 per share Appendix 3Y Change of Direc tor’s Interest Notice + See chapter 19 for defined te rms. Appendix 3Y P age 2 01/01/20 11 No. of securiti es he l d af ter change 5 68 , 815 Nature of chan ge Examp le: on - market trade, off - market trade, exercise of options, issue of securi ties under d ividend reinvestment plan, participation in buy - back Purchase of 38,505 shares via o n - market trade s via N aylor - S tewart I nvestm ents P t y L td a s T rustee for N aylor - S tewart F amily T rust Part 2 – C hange of director’s interests in c ontra cts Note: In the case of a company, interests wh ich come wi thin paragraph (ii) of the definition of “n otifiable interest of a direc tor” should be disclosed in this par t . Detail of contract Not applicable Nature of intere st Name of registered hol der ( if issued securities) Date of change No. and cl ass of s ecurities to which interest related prior t o change Note: Det a ils are on ly required for a contract in relati o n t o which the interest has changed Interest acquir ed Interest disposed Val ue/Co nsideration Note: If consideration is non - cash, p rov ide deta ils and an estimated valuation Interest after change P a rt 3 – + Cl osed period We re the interests in t h e s ecurities or contracts detailed above traded during a + closed period where prio r wri tten clearance was required? No If so, was prio r wr itten cl earance provided to allow the trade to proc eed during this pe r iod? N/A If prior writte n clearance was prov i ded , on what date was this provided? N/A
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Medical Developments International (ASX:MVP) when you join Listcorp.